Ex-Generic Drug Executive Charged in U.S. Price-Fixing Probe (1)

A former Taro Pharmaceutical Industries Ltd. marketing executive was charged by the U.S. Justice Department for conspiring to fix prices of generic drugs, the latest case to emerge from a years-long federal antitrust investigation.

Ara Aprahamian, who was responsible for overseeing generic-drug sales, pricing, and contracts at Taro, conspired with two companies to fix prices from 2013 to 2015, the Justice Department said in a statement on Tuesday. He was also charged with lying to the FBI.

“Today’s charges demonstrate the antitrust division’s resolve in rooting out collusion that corrupted the marketplace for generic drugs and led to higher ...